Clinical Trials

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

29 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT07092514 2026-03-17

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

34 enrolled

Head & Neck

Thyroid Neoplasms

NCT07466225 2026-03-12

HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion

Not yet recruiting

150 enrolled

Carcinoma, Hepatocellular

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

32 enrolled

Endometrial Neoplasms

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Carcinoma, Renal Cell

NCT06859684 2026-03-09

HAIC-quad

25 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

90 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

17 enrolled

Carcinoma, Renal Cell

NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Cholangiocarcinoma

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Recruiting

18 enrolled

Endometrial Neoplasms

NCT07419932 2026-02-19

NeoLATC

Recruiting

120 enrolled

Head & Neck

Thyroid Neoplasms

NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Phase NA Not yet recruiting

60 enrolled

Other solid neoplasm

Solid Tumors

NCT07417800 2026-02-18

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

1,000 enrolled

Carcinoma, Hepatocellular

NCT06669572 2026-02-17

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

35 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

38 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07389629 2026-02-05

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

25 enrolled

Carcinoma, Renal Cell

NCT06631326 2026-01-27

HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)

Completed

244 enrolled

Carcinoma, Hepatocellular

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Adenocarcinoma, Uterine Cervical Neoplasms

NCT05846724 2026-01-22

PULSAR

Phase 2 Withdrawn

Sarcoma

Sarcoma, Kaposi

NCT07359053 2026-01-22

MAGNATE-S

46 enrolled

Sarcoma

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Phase 1 Recruiting

72 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05327686 2026-01-14

SAMURAI

240 enrolled

Phase EARLY_PHASE1 Recruiting

Carcinoma, Renal Cell

NCT05041153 2026-01-12

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

15 enrolled

Phase 1 Active not recruiting

Advanced Gastric Adenocarcinoma

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

15 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT03950609 2026-01-09

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT06138496 2026-01-05

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Phase 2 Completed

39 enrolled

Carcinoma, Renal Cell

NCT05286437 2025-12-30

LaPemERLA

40 enrolled

Breast

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

NCT05532319 2025-12-30

FRONT-1

Phase 2 Completed

64 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06266338 2025-12-22

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Uterine Cervical Neoplasms

NCT07282184 2025-12-18

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

Phase 1/2 Recruiting

144 enrolled

Carcinoma, Hepatocellular

NCT07290894 2025-12-18

MITO VULVA-01

80 enrolled

Vulvar Neoplasms

NCT06110793 2025-12-17

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Phase 1/2 Recruiting

49 enrolled

Breast

Breast Neoplasms

NCT04207086 2025-12-16

Neo PeLe

21 enrolled

Dermatologic

Melanoma

NCT04427293 2025-12-16

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Phase 1 Recruiting

12 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

300 enrolled

Biliary Tract Neoplasms

NCT07277972 2025-12-11

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

36 enrolled

Carcinoma, Renal Cell

NCT06230471 2025-12-09

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

60 enrolled

Biliary Tract Neoplasms Immunotherapy

NCT03526679 2025-12-05

LEADER

Phase 1/2 Completed

30 enrolled 9 charts

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT07263360 2025-12-04

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

29 enrolled

BTC

NCT05433116 2025-12-02

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Recruiting

1,220 enrolled

CNSDermatologicGenitourinary

Carcinoma, Renal Cell

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Phase 2 Terminated

18 enrolled

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT05282901 2025-11-24

PLUME

51 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07149090 2025-11-20

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

Phase 1/2 Recruiting

61 enrolled

Stomach Neoplasms

NCT04887805 2025-11-19

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

28 enrolled

Pancreatic Neoplasms

NCT04869137 2025-10-31

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma